Glenmark Pharma receives USFDA approval to market generic diabetes drug

1 Aug 2023 , 12:51 PM

Glenmark Pharmaceuticals announced on Tuesday that it has received approval from the US health regulator to market its generic diabetic medicine in the United States.

The pharma company said in a statement that the US Food and Drug Administration (USFDA) has given final approval to Saxagliptin Tablets (2.5 mg and 5 mg), the generic version of AstraZeneca’s Onglyza1 tablets.

According to IQVIATM sales data, the Onglyza tablets (2.5 mg and 5 mg) registered annual sales of roughly USD 100.7 million for the 12-month period ending June 2023.

Glenmark stated that its current portfolio now includes 184 medications that are permitted for distribution in the US market, as well as 49 abbreviated new drug applications (ANDAs) that are awaiting approval from the USFDA.

At around 12.47 PM, Glenmark Pharmaceuticals was trading at Rs 785.15, down by 0.34% against the previous close of Rs 787.85 on NSE.

For feedback and suggestions, write to us at [e-mail]